Evidence map›Paper›PMID 28753864›Full record

ArticleEuropean urology focus2018

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Jennifer Cullen, Denise Young, Yongmei Chen, Michael Degon, James Farrell, Jason Sedarsky, Wagner Baptiste, Philip Rosen, Vladimir Tolstikov, Michael Kiebish and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology focus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Pooled it
  2. Pooled it
  3. Genes · 2023
    Article
  4. Association ofBiomedicines · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Jennifer CullenCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. Electronic address: jcullen@cpdr.org.
Denise YoungCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Yongmei ChenCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Michael DegonCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Walter Reed National Military Medical Center, Urology Service, Bethesda, MD, USA.
James FarrellCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Walter Reed National Military Medical Center, Urology Service, Bethesda, MD, USA.
Jason SedarskyCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Walter Reed National Military Medical Center, Urology Service, Bethesda, MD, USA.
Wagner BaptisteCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Walter Reed National Military Medical Center, Urology Service, Bethesda, MD, USA.
Philip RosenCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Walter Reed National Military Medical Center, Urology Service, Bethesda, MD, USA.
Vladimir TolstikovBERG Health, Framingham, MA, USA.
Michael KiebishBERG Health, Framingham, MA, USA.
Jacob KaganCancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Sudhir SrivastavaCancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Huai-Ching KuoCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Joel T MoncurWalter Reed National Military Medical Center, Urology Service, Bethesda, MD, USA.
Inger L RosnerCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Walter Reed National Military Medical Center, Urology Service, Bethesda, MD, USA.
Niven NarainBERG Health, Framingham, MA, USA.
Viatcheslav AkmaevBERG Health, Framingham, MA, USA.
Gyorgy PetrovicsCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Albert DobiCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
David G McLeodCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Walter Reed National Military Medical Center, Urology Service, Bethesda, MD, USA.
Shiv SrivastavaCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Isabell A SesterhennCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Joint Pathology Center, Silver Spring, MD, USA.
Uniformed Services University of the Health Sciences · USNational Cancer Institute · USWalter Reed National Military Medical Center · US

Funding

Cell Specific Expression Signatures in Prostate Cancer (RO1 DK065977)R01CA162383 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SRIVASTAVA, SHIV · 2011 to 2015
$1.1M
Cell Specific Expression Signatures in Prostate CancerR01DK065977 · NIDDK · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SRIVASTAVA, SHIV · 2004 to 2007
$688k
Intramural NIH HHS Z99 CA999999NCI NIH HHS R01 CA162383NIDDK NIH HHS R01 DK065977
6 · The paper itself

Abstract

backgroundETS-related gene (ERG) oncogenic activation is the most common genomic alteration in prostate cancer (CaP) although it occurs less frequently in African American (AA) versus Caucasian (CA) patients, and the potential role of ERG as a prognostic marker has not been confirmed.

objectiveThis study was conducted to confirm strong racial variation in the prevalence of ERG oncoprotein expression and to examine ERG oncoprotein expression, race, and body mass index as independent and joint predictors of CaP biochemical recurrence (BCR) following radical prostatectomy (RP). DESIGN, SETTING, AND

participantsA retrospective cohort study of CA and AA CaP patients enrolled at Walter Reed National Military Medical Center, who donated clinically annotated, whole-mounted, prostatectomy specimens between 1994 and 2014 following RP, was conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier (KM) estimation curves and multivariable Cox proportional hazards models were used to examine time to BCR as a function of ERG status, patient race, and obesity. RESULTS AND LIMITATIONS: Among 930 eligible patients (36.1% AA and 63.9% CA), with 155 (16.7%) BCR events and a median follow-up time of 5.1 yr, ERG oncoprotein expression was significantly less prevalent in index tumors of AA versus CA patients (23.2% vs 49.3%; p<0.0001). KM curves showed significantly poorer BCR-free survival for CA patients with ERG-negative index tumors but not for AA patients. Race-stratified multivariable analyses revealed a significant association between ERG-negative index tumors and poorer BCR-free survival among CA patients (hazards ratio=1.67, confidence interval=1.07, 2.61; p=0.024). Less heterogeneity in ERG expression among AA patients may reduce the ability to show its association with BCR.

conclusionsStriking racial variation in ERG oncoprotein expression was confirmed. A novel observation was the importance of index tumor ERG-negative status in predicting CaP progression for CA patients. PATIENT SUMMARY: ETS-related gene (ERG) typing of tumors may be useful in prognosticating prostate cancer aggressiveness.

Indexed as

Black or African AmericanWhite PeopleAdultAgedCohort StudiesDisease ProgressionHumansKallikreinsKaplan-Meier EstimateLongitudinal StudiesMaleMiddle AgedNeoplasm Recurrence, LocalObesityProportional Hazards ModelsProstatectomyERG protein, humanKallikreinsKLK3 protein, humanProstate-Specific AntigenTranscriptional Regulator ERGBiochemical recurrenceERG fusionObesityProstate cancerRace

Identifiers

PMID28753864
PMCPMC7061732
OpenAlexW2592435180

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.